Expres2ion Biotech

 

CLICK HERE FOR INFORMATION ABOUT THE 2022 RIGHTS ISSUE

Financial Calendar

• 18/08/22

  Half-year report, 2022

• 17/11/22

  Interim report, Q3 2022

• 09/02/23

  Year-end report, 2022

Latest press releases

ExpreS2ion will participate in key industry and investor events

15-08-2022 Non-regulatory pressrelease

Hørsholm, Denmark, August 15, 2022 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") will participate and hold presentations at key industry and investor events in the coming month. These include a presentation of Q2 2022 results (August 18), the LSX Nordic Investor Conference (September 6-7), and PIVAC-22, a forum covering the most recent…

Read more

ExpreS2ion announces exercise of 2019 warrant program, second tranche of three

10-08-2022 Regulatory pressrelease

Hørsholm, Denmark, August 10, 2022 – ExpreS2ion Biotech Holding AB (“ExpreS2ion”) today announces that 136,422 warrants held by employees under the 2019 Warrant Program (“TO2”) have been fully exercised, providing ExpreS2ion SEK 656,190. The exercise has increased the number of shares by 136,422 from 37,162,106 to 37,298,528.

Read more

View all